Ehud Zeltzer, MD
Neurology · Indiana, PANPI 1558100503
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.4% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 168 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$457
- Teva Pharmaceuticals USA, Inc.$231
- Eisai Inc.$224
- Vanda Pharmaceuticals Inc.$210
- Biogen$190
- Acadia Pharmaceuticals Inc$168
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,28194%
- Education$1936%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $457 |
| Teva Pharmaceuticals USA, Inc. | 5 | $231 |
| Eisai Inc. | 14 | $224 |
| Vanda Pharmaceuticals Inc. | 11 | $210 |
| Biogen | 10 | $190 |
| Acadia Pharmaceuticals Inc | 8 | $168 |
| UCB, Inc. | 6 | $142 |
| TG Therapeutics, Inc. | 4 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $137 |
| Argenx US, Inc. | 6 | $126 |
| Amneal Pharmaceuticals LLC | 6 | $122 |
| Pfizer | 6 | $111 |
| SK Life Science, Inc. | 4 | $110 |
| EMD Serono, Inc. | 4 | $103 |
| AstraZeneca(2 entities) | 4 | $101 |
| Neurocrine Biosciences, Inc. | 4 | $99 |
| Grifols USA, LLC | 3 | $87 |
| Bristol Myers Squibb | 5 | $83 |
| Tanabe Pharma America, Inc. | 3 | $74 |
| GE HealthCare | 1 | $73 |
| Genentech USA, Inc. | 4 | $68 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Averitas Pharma Inc. | 2 | $55 |
| Lilly USA, LLC | 3 | $51 |
| Life Molecular Imaging Ltd | 2 | $40 |
| Lundbeck LLC | 2 | $35 |
| Novartis | 2 | $34 |
| Cycle Pharmaceuticals Inc | 2 | $32 |
| Johnson & Johnson | 1 | $30 |
| Microtransponder, Inc. | 1 | $23 |
| MDD US Operations, LLC | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Amgen | 1 | $17 |
How this compares
$3,474 in reported general payments places this provider in the 65th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 12 | $1,056 |
| Memantine Hcl | 13 | $238 |
| Donepezil Hcl | 26 | $146 |
| Levetiracetam | 11 | $70 |
| Escitalopram Oxalate | 11 | $16 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indiana
- Michael SauterIndiana$273K
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.